Proteomics-based evaluation of AAV dystrophin gene therapy outcomes in mdx skeletal muscle Apr 24， 2026 The 2026 jci.insight by Johnson, E.E., et al. researches Proteomics-based
Comparative characterization of Cas12f orthologs reveals mechanistic features underlying enhanced genome editing efficiency Apr 17， 2026 The 2026 Nature structural & molecular biology by Guan,
Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier Apr 10， 2026 The 2022 Cell Reports Methods by Shin,
Radiotherapy synergizes with an inducible AAV-based immunotherapy platform to program local and systemic antitumor immunity Apr 3， 2026 The 2026 Cancer Cell paper by Marco,
In vivo site-specific engineering to reprogram T cells Mar 27， 2026 The 2026 Nature paper by Nyberg, W.A. et al researches in vivo site-specific engineering
Inter-individual variability in immune response to AAV ocular gene delivery across species impedes immunomonitoring Mar 20， 2026 The 2026 JCI Insight paper by Duohao REN
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines Mar 13， 2026 The 2025 Signal Transduction and Targeted
Comprehensive Review of Blood-Brain Barrier-Penetrating Adeno-Associated Virus (AAV) Capsid Engineering for Central Nervous System (CNS) Gene Therapy Mar 6， 2026 Introduction The central nervous system
Engineered UGA Suppressor tRNA: A Breakthrough in Disease-Agnostic AAV Gene Therapy Feb 27， 2026 The 2025 nature biotechnology paper by Dan Xu et al presents